ZLD — Zelira Therapeutics Balance Sheet
0.000.00%
- AU$4.16m
- AU$6.47m
- AU$0.00m
Annual balance sheet for Zelira Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 4.97 | 2.75 | 0.146 | 0.586 | 0.006 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.052 | 0.25 | -0.008 | 2.15 | 0.025 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6.09 | 5.08 | 1.77 | 4.26 | 0.614 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.24 | 0.848 | 0.519 | 0.225 | 0.122 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 39.4 | 37.7 | 33.9 | 5.18 | 1.3 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.08 | 1.63 | 1.88 | 7.09 | 5.59 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 1.54 | 2.5 | 2.09 | 9.7 | 5.76 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 37.8 | 35.2 | 31.8 | -4.51 | -4.46 |
| Total Liabilities & Shareholders' Equity | 39.4 | 37.7 | 33.9 | 5.18 | 1.3 |
| Total Common Shares Outstanding |